Hormonal diseases

146 trials 57 recruiting

Filter these 146 trials by phase, country and sponsor.

Open in Search →

Tiratricol treatment of children with Monocarboxylate Transporter 8 deficiency: Triac Trial II Ended

2024-516123-13-00 Monocarboxylate Transporter 8 (MCT8) deficiency 4 2021-02-03
A study of safety and efficacy of NBI-74788 in Classic Congenital Adrenal Hyperplasia Ended

2023-509171-16-00 Classic Congenital Adrenal Hyperplasia (CAH) 5 2020-11-23
A research study in children born small and who stayed small. Treatment is somapacitan once a week compared to Norditropin® once a day Ended

2023-506830-66-00 SGA - small for gestational age children 4 2019-05-29
Randomized phase 2 trial of two chemotherapy regimens plus or minus bevacizumab in patients with well differentiated pancreatic neuroendocri… Ended

2023-505286-84-00 Pancreatic well differentiated neuroendocrine tumors (N 4 2018-06-25
Phase 2 Study of ALXN2420 versus Placebo in Combination with Somatostatin Analogs in Participants with Acromegaly Halted

2025-521243-20-00 Acromegaly 4 2025-10-23
Premixed glucagon/insulin solution for faster insulin absorption in Type 1 diabetes. Halted

2023-510408-32-02 Type 1 diabetes 4 2025-04-01
A Trial to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Insulin GZR33 Compared with Insulin Degludec at stea… Ended

2025-523052-32-00 Type 1 diabetes Mellitus 3 2025-10-17
A single-center pilot study to establish a novel hypoglycemic clamp procedure to assess the time to spontaneous recovery from hypoglycemia i… Ended

2025-520996-16-00 Type 2 Diabetes Mellitus 9 2025-07-02
A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on Dapagliflozin 10 mg film-coated t… Ended

2024-520212-18-00 intended for treatment of for the treatment of (2): • 2 2025-04-03
Impact of 18F-FES TEP on therapeutical management in patients with metastatic breast cancer, ER positive and HER2 negative, in relapse after… Ended

2024-517400-11-00 Patients with metastatic breast cancer initially presen 6 2024-10-24
Identifying Individuals at Risk of Glucocorticoid-Induced Impairment of Bone Disease (RIGID Ended

2023-506949-27-00 Secondary Osteoporosis 4 2024-10-14
SPI-62 as a treatment for adrenocorticotropic hormone-dependent Cushing’s syndrome Ended

2024-515913-17-00 Cushing's Syndrome 4 2024-10-10
Personalized Treatment Optimization for Kidney Health in Type 2 Diabetes: A Remote Trial with Empagliflozin and Finerenone Ended

2023-508585-15-00 Albuminuria 6 2024-07-29
A phase 1 study to assess the mass balance, pharmacokinetics, metabolism, and excretion of GSBR-1290, containing a microtracer dose of [14C]… Ended

2024-512578-83-00 Not applicable - Healthy volonteers 3 2024-06-24
Tirzepatide, a new drug for type 2 diabetes mellitus and obesity, as a possible treatment to modify the clinical evolution of Wolfram syndro… Ended

2024-514909-64-00 Wolfram syndrome type 1 4 2024-05-16
A Phase 1, open label, randomized, 2-sequence, 2-period, crossover, single center study to evaluate the pharmacokinetics of follitropin alfa… Ended

2023-507066-91-00 Infertility 3 2024-03-19
Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants with Congenital Adrenal Hyperplasia Ended

2023-503488-40-00 CONGENITAL ADRENAL HYPERPLASIA 4 2023-11-27
A study to see how well PLS240 works in treating secondary hyperparathyroidism, and how safe it is, in end stage kidney disease participants… Ended

2023-504338-24-00 ESKD participants with history of secondary hyperparath 5 2023-11-09
A study to see how well PLS240 works in treating secondary hyperparathyroidism, and how safe it is, in end stage kidney disease participants… Ended

2023-504339-41-00 ESKD participants with history of secondary hyperparath 5 2023-11-08
Effects of empagliflozin on plasma glucose in patients with HNF1A-MODY: a randomized, double-blind, crossover trial Ended

2023-503760-17-00 Maturity-onset diabetes of the young type 3 (HNF1A-MODY 4 2023-10-11
A study to learn about how much elinzanetant gets absorbed in the blood and how safe it is in healthy participants when taken as different t… Ended

2023-503968-16-00 Vasomotor symptoms as a sex hormone-dependent disorder 3 2023-09-25
A study to learn how much elinzanetant gets into the blood, how safe it is and how it affects the body after taking single and multiple amou… Ended

2023-503864-17-00 Vasomotor Symptoms as a sex hormone-dependent disorder 3 2023-09-20
Senolytics to Improve Osteoporosis therapy: A randomised controlled clinical trial The SENIOR Trial Ended

2022-502076-23-00 osteopenia 4 2023-08-16
Withdrawal of Tiratricol Treatment in Males with Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency): A Double-blind, Randomized, Pla… Ended

2024-516124-34-00 Monocarboxylate Transporter 8 (MCT8) deficiency 5 2023-07-21